^Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (August 2004). "Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 370 (2): 114–23. doi:10.1007/s00210-004-0951-4. PMID15322733. S2CID8938111.
^Halford JC, Harrold JA, Lawton CL, Blundell JE (March 2005). "Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity". Current Drug Targets. 6 (2): 201–13. doi:10.2174/1389450053174550. PMID15777190.
^Schuhler S, Clark A, Joseph W, Patel A, Lehnen K, Stratford E, Horan TL, Fone KC, Ebling FJ (May 2005). "Involvement of 5-HT receptors in the regulation of food intake in Siberian hamsters". Journal of Neuroendocrinology. 17 (5): 276–85. doi:10.1111/j.1365-2826.2005.01303.x. PMID15869562. S2CID31333248.
^Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, Sherf B, Harrington J, Brunden K, Stricker-Krongrad A (December 2005). "Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes". ASSAY and Drug Development Technologies. 3 (6): 649–59. doi:10.1089/adt.2005.3.649. PMID16438660.